Erratum: Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

Correction to: Cell Research (2015) 25:208–224. doi:10.1038/cr.2015.3; published online 13 January 2015

The authors apologize for omission of two authors, Inka Zörnig (Department of Medical Oncology, National Center for Tumor Diseases and Heidelberg University Hospital, Heidelberg, Germany) and Jessica Hassel (Department of Dermatology, National Center for Tumor Diseases and Heidelberg University Hospital, Heidelberg, Germany), in the author list. The full author list should be:

Dalil Hannani^{1, 2, 3}, Marie Vétizou^{1, 2, 3}, David Enot^{1, 4, 5}, Sylvie Rusakiewicz^{1, 2, 6}, Nathalie Chaput^{1, 2, 6}, David Klatzmann^{7, 8}, Melanie Desbois^{1, 2, 6}, Nicolas Jacquelot^{1, 2, 3}, Nadège Vimond^{1, 2, 6}, Salem Chouaib⁹, Christine Mateus^{1, 10}, James P Allison¹¹, Antoni Ribas¹², Jedd D Wolchok¹³, Jianda Yuan¹³, Philip Wong¹³, Michael Postow¹³, Andrzej Mackiewicz^{14, 15}, Jacek Mackiewicz^{14, 15}, Dirk Schadendorff¹⁶, Dirk Jaeger¹⁷, Inka Zörnig¹⁷, Jessica Hassel¹⁸, Alan J Korman¹⁹, Keith Bahjat²⁰, Michele Maio²¹, Luana Calabro²¹, Michele WL Teng^{22, 23}, Mark J Smyth^{22, 23}, Alexander Eggermont^{1, 2, 24}, Caroline Robert^{1, 2, 10, 24}, Guido Kroemer^{1, 4, 5, 25, 26, 27}, Laurence Zitvogel^{1, 2, 3, 10}

¹Gustave Roussy Cancer Campus, Villejuif, France; ²INSERM U1015, Villejuif, France; ³Université Paris Sud-XI, Faculté de Médecine, Le Kremlin Bicêtre, France; ⁴INSERM U848, Villejuif, France; ⁵Metabolomics Platform, Institut Gustave Roussy, Villejuif, France; ⁶Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France; ⁷INSERM, Unité Mixte de Recherche_S959, I³, Paris, France; ⁸Assistance-Publique Hopitaux de Paris, Hôpital Pitié-Salpêtrière, Biotherapy, Paris, France; ⁹INSERM U753, Villejuif, France; ¹⁰Department of Medical Oncology, IGR, Villejuif, France; ¹¹Department of Immunology, MD Anderson Cancer Center, Houston, TX, USA; ¹²University of California Los Angeles, Los Angeles, CA, USA; ¹³Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ¹⁴Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, Poznan, Poland; ¹⁵Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland; ¹⁶Department of Dermatology, University Hospital Essen, Germany; ¹⁷Department of Medical Oncology, National Center for Tumor Diseases and Heidelberg University Hospital, Heidelberg, Germany; ¹⁸Department of Dermatology, National Center for Tumor Diseases and Heidelberg University Hospital, Heidelberg, Germany; ¹⁹Bristol-Myers Squibb, Redwood City, CA, USA; ²⁰Earle A Chiles Research Institute, Robert W Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA; ²¹Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; ²²QIMR Berghofer Medical Research Institute, Herston, 4006, Queensland, Australia; ²³School of Medicine, The University of Queensland, Herston, QLD 4006, Queensland, Australia; ²⁴INSERM U981, Villejuif, France; ²⁵Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U 1138, Paris, France; ²⁶Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; ²⁷Université Paris Des-cartes, Sorbonne Paris Cité, Paris, France

In addition, some patient samples originally described as from German Cancer Research Center were indeed provided by Heidelberg University Hospital (Heidelberg, Germany):

(p218, right column, line 1-5): “Patient samples (plasma or sera) were provided by..... The German Cancer Research Center (Heidelberg, Germany)...” should be “Patient samples (plasma or sera) were provided by..... Heidelberg University Hospital (Heidelberg, Germany)...”.